Nicolas Ruffin
Overview
Explore the profile of Nicolas Ruffin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
768
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu Y, Deeba E, Klappe U, Oijerstedt L, Andersson J, Ruffin N, et al.
Brain Behav Immun Health
. 2024 Dec;
42:100907.
PMID: 39650285
Background: Amyotrophic lateral sclerosis (ALS) represents a complex syndrome characterized by motor, psychiatric, and cognitive symptoms, where associations between cellular immune features and non-motor manifestations remain unknown. Methods: In this...
2.
Richter F, Gea-Mallorqui E, Mortha A, Ruffin N, Vabret N
Nature
. 2023 Jun;
PMID: 37264129
No abstract available.
3.
Richter F, Gea-Mallorqui E, Mortha A, Ruffin N, Vabret N
EMBO Rep
. 2023 May;
24(6):e57258.
PMID: 37161695
Cross-institutional journal clubs focused on preprints are a new approach to community-based peer review and allow ERCs to gain experience.
4.
Brouiller F, Nadalin F, Bonte P, Ait-Mohamed O, Delaugerre C, Lelievre J, et al.
iScience
. 2023 Mar;
26(2):106019.
PMID: 36866043
Sensing of incoming viruses is a pivotal task of dendritic cells (DCs). Human primary blood DCs encompass various subsets that are diverse in their susceptibility and response to HIV-1. The...
5.
Cucuzza C, Longinetti E, Ruffin N, Evertsson B, Kockum I, Jagodic M, et al.
Neurol Neuroimmunol Neuroinflamm
. 2022 Nov;
10(1).
PMID: 36411076
Background And Objectives: B cell-depleting therapies are highly effective in relapsing-remitting multiple sclerosis (RRMS) but are associated with increased infection risk and blunted humoral vaccination responses. Extension of dosing intervals...
6.
Ruffin N, Gea-Mallorqui E
Nat Rev Immunol
. 2022 Nov;
22(12):715.
PMID: 36316572
No abstract available.
7.
Asplund Hogelin K, Ruffin N, Pin E, Hober S, Nilsson P, Cucuzza C, et al.
Eur J Neurol
. 2022 Jul;
29(11):3317-3328.
PMID: 35808856
Background And Purpose: Recent findings document a blunted humoral response to SARS-CoV-2 vaccination in patients on anti-CD20 treatment. Although most patients develop a cellular response, it is still important to...
8.
Cui C, Ingre C, Yin L, Li X, Andersson J, Seitz C, et al.
Elife
. 2022 Mar;
11.
PMID: 35287794
The prognostic role of immune cells in amyotrophic lateral sclerosis (ALS) remains undetermined. Therefore, we conducted a longitudinal cohort study including 288 ALS patients with up to 5-year follow-up during...
9.
Ruffin N, Guerreiro-Cacais A
Nat Rev Immunol
. 2021 Dec;
22(2):74.
PMID: 34912107
No abstract available.
10.
Asplund Hogelin K, Ruffin N, Pin E, Manberg A, Hober S, Gafvelin G, et al.
iScience
. 2021 Sep;
24(9):103078.
PMID: 34490414
B cell depleting therapies (BCDTs) are widely used as immunomodulating agents for autoimmune diseases such as multiple sclerosis. Their possible impact on development of immunity to severe acute respiratory syndrome...